Interaction between human angiogenin and the p53 TAD2 domain and its implication for inhibitor discovery

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• The p53 tumor suppressor is crucial for preventing cancer.
• Angiogenin is implicated in tumor growth and angiogenesis.
• Interaction between angiogenin and p53 can impair p53's tumor-suppressive functions.

Purpose of the Study:

• To elucidate the molecular mechanism of angiogenin interaction with the p53 TAD2 domain.
• To identify specific binding sites on angiogenin responsible for p53 interaction.
• To explore therapeutic strategies targeting this interaction for cancer treatment.

Main Methods:

• Nuclear Magnetic Resonance (NMR) spectroscopy to determine structural interactions.
• Site-directed mutagenesis to analyze the role of specific amino acid residues.
• Computational modeling to predict binding interfaces.

Main Results:

• Positively charged RRR (residues 31-33) and KRSIK (residues 50-54) motifs on angiogenin were identified as key p53-binding sites.
• These angiogenin motifs interact with negatively charged residues (D48/E51 and E56) in the p53 TAD2 domain.
• This interaction inhibits p53-mediated apoptosis and promotes cancer cell survival and angiogenesis.

Conclusions:

• The RRR and KRSIK motifs of angiogenin are critical for binding and inhibiting p53 function in cancer cells.
• These findings highlight potential therapeutic targets for developing angiogenin-specific inhibitors.
• Inhibitors could simultaneously block angiogenin's binding, internalization, DNA binding, and nuclear translocation, offering a novel anti-cancer approach.